GLAXOSMITHKLINE, LLC: $793M Department of Health and Human Services Contract Vehicle
Summary
This contract is a $793 million indefinite delivery/indefinite quantity award to GlaxoSmithKline, LLC for vaccines under the Vaccines for Children program for FY25. The recipient is a private entity, so there is no direct public company beneficiary, but the contract underscores the ongoing federal commitment to pediatric vaccination programs.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.GlaxoSmithKline, LLC is a private entity, so no public company directly books this $793M contract.
- 2.The Vaccines for Children program is a recurring federal initiative, reinforcing steady demand for pediatric vaccines.
- 3.Investors should monitor for subcontracting opportunities or supply chain contracts that may involve publicly traded firms.
Market Implications
Since the contract recipient is private, there is no direct equity impact. The broader healthcare sector remains supported by consistent federal vaccine spending, but without a specific public company tied to this award, market implications are muted. Investors may look to other publicly traded vaccine makers for similar contract opportunities, but this particular award does not change their prospects.
Full Analysis
The Department of Health and Human Services, through the CDC, awarded GlaxoSmithKline, LLC a $793 million contract for the Vaccines for Children (VFC) program for FY25. The VFC program provides vaccines to children who are uninsured, underinsured, or eligible for Medicaid. GlaxoSmithKline, LLC is a private entity, meaning no publicly traded company directly captures this revenue. However, the contract signals sustained government spending on childhood immunization, which supports the broader healthcare sector, particularly vaccine development and distribution infrastructure. The contract is structured as an indefinite delivery/indefinite quantity, typical for multi-year procurement, and runs from April 2025 to March 2026. Despite its large size, this is a routine annual renewal for a well-established program, not a new initiative. No bill signals from the provided list directly relate to this contract, and the private nature of the recipient limits direct public market implications. Historically, the VFC program has been a stable funding stream for vaccine manufacturers, but in this case, the benefit accrues to a private company, leaving no straightforward equity play.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DEPARTMENT OF HUMAN SERVICES HAWAII: $2.2B Department of Health and Human Services Grant
KANSAS DEPARTMENT OF HEALTH & ENVIRONMENT: $4.6B Department of Health and Human Services Grant
NEW MEXICO HEALTH CARE AUTHORITY: $9.4B Department of Health and Human Services Grant
HEALTH SERVICES KENTUCKY CABINET FOR: $18.2B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.1B Department of Health and Human Services Federal Award
ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM: $19.6B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
HEALTH CARE SERVICES, CALIFORNIA DEPARTMENT OF: $6.2B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Contract Details
Recipient
GLAXOSMITHKLINE, LLC
Award Amount
$793,016,570
Awarding Agency
Department of Health and Human Services
Sub-Agency
Centers for Disease Control and Prevention
Contract Type
INDEFINITE DELIVERY / INDEFINITE QUANTITY
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →